AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Albemarle Pref A ADR: 15min chart sees MACD Death Cross, Bearish Marubozu
ByAinvest
Monday, Oct 20, 2025 1:57 pm ET1min read
According to the 15-minute chart of Albemarle Pref A ADR, a MACD Death Cross has occurred, accompanied by a Bearish Marubozu at 10/20/2025 13:45. This indicates that the stock price has the potential to continue declining, as sellers are currently dominating the market, and bearish momentum is likely to persist.
Agilent Technologies Inc. (NYSE:A) reported earnings per share (EPS) of $1.37 for the last quarter, meeting analysts' expectations, while revenue increased by 10.1% year-over-year to $1.74 billion, according to a MarketBeat alert . The company also announced a quarterly dividend of $0.248 per share, with an annualized yield of 0.7%, reflecting a payout ratio of 23.24%.Concurrent Investment Advisors LLC bought a new stake in Agilent Technologies during the second quarter, according to the same MarketBeat alert. The firm bought 2,260 shares of the medical research company's stock, valued at approximately $267,000.
Other hedge funds have also made changes to their positions in the company. Stone House Investment Management LLC purchased a new position in shares of Agilent Technologies in the 1st quarter valued at $30,000. Ransom Advisory Ltd purchased a new position in shares of Agilent Technologies in the 1st quarter valued at $32,000. Central Pacific Bank Trust Division purchased a new position in shares of Agilent Technologies in the 2nd quarter valued at $33,000. Zions Bancorporation National Association UT purchased a new position in shares of Agilent Technologies in the 1st quarter valued at $38,000. Finally, Costello Asset Management INC purchased a new position in shares of Agilent Technologies in the 1st quarter valued at $47,000, as noted in the MarketBeat alert.
Analysts have responded positively to Agilent Technologies' earnings report. Weiss Ratings reaffirmed a "hold (c)" rating on shares of Agilent Technologies. Rothschild Redb raised shares of Agilent Technologies to a "strong-buy" rating. Wall Street Zen raised shares of Agilent Technologies from a "hold" rating to a "buy" rating. Barclays lifted their price target on shares of Agilent Technologies from $125.00 to $150.00 and gave the stock an "equal weight" rating. UBS Group raised shares of Agilent Technologies from a "neutral" rating to a "buy" rating and lifted their price target for the stock from $130.00 to $170.00 — details reported in the MarketBeat alert.
Agilent Technologies, Inc. has a market capitalization of $40.26 billion, a P/E ratio of 33.34, a PEG ratio of 4.63, and a beta of 1.26. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.71, and a current ratio of 2.25, according to the MarketBeat alert.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet